Baidu
map

JAMA:非心脏手术围手术期使用β-受体阻滞剂或可降低患者死亡率

2013-04-25 JAMA dxy

非心脏手术围手术期应用β-受体阻滞剂治疗的有效性仍存在争议。美国圣弗朗西斯科麻醉医学中心Martin J. London博士及其同事对此进行了深入研究,旨在明确非心脏手术早围手术期使用β-受体阻滞剂治疗与术后30天结局之间的关系。他们的研究发现,对于接受非心脏手术、非血管性手术的倾向性得分匹配的人群来说,围手术期使用β-受体阻滞剂可引起存在2项或更多项改良心脏风险指数因素的患者30天全因死亡率减少

非心脏手术围手术期应用β-受体阻滞剂治疗的有效性仍存在争议。美国圣弗朗西斯科麻醉医学中心Martin J. London博士及其同事对此进行了深入研究,旨在明确非心脏手术早围手术期使用β-受体阻滞剂治疗与术后30天结局之间的关系。他们的研究发现,对于接受非心脏手术、非血管性手术的倾向性得分匹配的人群来说,围手术期使用β-受体阻滞剂可引起存在2项或更多项改良心脏风险指数因素的患者30天全因死亡率减少。这些发现支持将改良心脏风险指数因素的累积数目作为围手术期开始或连续给予β-受体阻滞剂治疗的决策指标。相关成果发表于2013年4月最新一期的JAMA在线版上。
这一回顾性队列分析评估了非心脏手术围手术期或术后β-受体阻滞剂治疗的效应,纳入样本包括2005年1月至2010年8月在104家VA医疗中心接受治疗的基于人群样本的136745例患者,并按倾向性得分1:1比例纳入对照受试者37805例。主要结局为30天全因死亡率及心脏事件发生率(心跳停止或Q波心肌梗死)。
结果显示,总共有55138例患者(40.3%)暴露于β-受体阻滞剂。与接受非血管手术的患者(95% CI, 37.1%-37.6%; P < .001)相比,接受血管手术的患者暴露率更高(95% CI, 65.9%-67.5%),两者暴露率分别为37.4% VS 66.7%,病例基数分别为122 882例和13 863例。研究者发现,随着改良心危险指数因素的增多,暴露率就越高:无风险因素时β-受体阻滞剂暴露率为25.3% (95% CI, 24.9%-25.6%),存在4项风险因素时暴露率则为71.3% (95% CI, 69.5%-73.2%)(P < .001)或更多。总死亡率为1.1% (95% CI, 1.1%-1.2%),心脏事件死亡率为0.9% (95% CI, 0.8%-0.9%)。在倾向性得分匹配队列中,发现暴露与死亡率降低相关(相对危险值[RR], 0.73; 95% CI, 0.65-0.83; P < .001; 需治疗的病例数[NNT], 241; 95% CI, 173-397)。当就改良心危险指数因素的积累数目进行分层后分析得知,β-受体阻滞剂可引起存在2个危险因素(RR, 0.63 [95% CI, 0.50-0.80]; P < .001; NNT, 105 [95% CI, 69-212]),3个危险因素(RR, 0.54 [95% CI, 0.39-0.73]; P < .001; NNT, 41 [95% CI, 28-80])或4个危险因素或更多(RR, 0.40 [95% CI, 0.25-0.73]; P < .001; NNT, 18 [95% CI, 12-34])的患者的死亡率显著性降低。研究人员发现,这些关联仅限于接受非血管性手术的患者人群。β-受体阻滞剂暴露可引起非致命性Q波心肌梗死或心动停止发生率降低(RR, 0.67 [95% CI, 0.57-0.79]; P < .001; NNT, 339 [95% CI, 240-582]),同样仅限于接受非血管性手术患者人群。
冠心病及其高危患者进行非心脏手术时,围手术期心脏事件(如死亡、卒中、心肌梗死等)的危险性显著增加。其机制较为复杂,其中儿茶酚胺水平升高以及心动过速可能与不良心脏事件的发生具有密切关系。鉴于此,多数学者认为在围手术期为患者应用β-受体阻滞剂可对心血管系统起到有效保护作用。根据有限的研究证据,不久前ACC/AHA颁布的指南建议为接受非心脏手术的心血管高危患者围手术期应用β-受体阻滞剂,并将其静息心率控制在50-60次/分范围内。
对于接受非心脏手术的冠心病及其高危患者,由于围手术期的精神紧张、术中血容量的改变、麻醉及其他药物的应用等因素,可能显著增加心血管系统负担并提高心率以及交感神经系统兴奋水平,导致发生心脏事件的危险性增加。从病理生理机制而论,应用β-受体阻滞剂可能会对心血管系统具有保护作用。因此国外相关指南中推荐为此类患者在围手术期应用b-受体阻滞剂。
本研究得出的结论是:对于接受非心脏手术、非血管性手术的倾向性得分匹配的人群来说,围手术期使用β-受体阻滞剂可引起存在2项或更多项改良心脏风险指数因素的患者30天全因死亡率减少。这些发现支持将改良心脏风险指数因素的累积数目作为围手术期开始或连续给予β-受体阻滞剂治疗的决策指标。当然这一研究结果还需要进行多中心随机试验以对就风险因素分类为低危至中危的患者人群中予以证实。
β受体相关的拓展阅读:


Association of Perioperative β-Blockade With Mortality and Cardiovascular Morbidity Following Major Noncardiac Surgery
Importance 
The effectiveness of perioperative β-blockade in patients undergoing noncardiac surgery remains controversial.
Objective 
To determine the associations of early perioperative exposure to β-blockers with 30-day postoperative outcome in patients undergoing noncardiac surgery.
Design, Setting, and Patients 
A retrospective cohort analysis evaluating exposure to β-blockers on the day of or following major noncardiac surgery among a population-based sample of 136 745 patients who were 1:1 matched on propensity scores (37 805 matched pairs) treated at 104 VA medical centers from January 2005 through August 2010.
Main Outcomes and Measures 
All cause 30-day mortality and cardiac morbidity (cardiac arrest or Q-wave myocardial infarction).
Results 
Overall 55 138 patients (40.3%) were exposed to β-blockers. Exposure was higher in the 66.7% of 13 863 patients undergoing vascular surgery (95% CI, 65.9%-67.5%) than in the 37.4% of 122 882 patients undergoing nonvascular surgery (95% CI, 37.1%-37.6%; P < .001). Exposure increased as Revised Cardiac Risk Index factors increased, with 25.3% (95% CI, 24.9%-25.6%) of those with no risk vs 71.3% (95% CI, 69.5%-73.2%) of those with 4 risk factors or more exposed to β-blockers (P < .001). Death occurred among 1.1% (95% CI, 1.1%-1.2%) and cardiac morbidity occurred among 0.9% (95% CI, 0.8%-0.9%) of patients. In the propensity matched cohort, exposure was associated with lower mortality (relative risk [RR], 0.73; 95% CI, 0.65-0.83; P < .001; number need to treat [NNT], 241; 95% CI, 173-397). When stratified by cumulative numbers of Revised Cardiac Risk Index factors, β-blocker exposure was associated with significantly lower mortality among patients with 2 factors (RR, 0.63 [95% CI, 0.50-0.80]; P < .001; NNT, 105 [95% CI, 69-212]), 3 factors (RR, 0.54 [95% CI, 0.39-0.73]; P < .001; NNT, 41 [95% CI, 28-80]), or 4 factors or more (RR, 0.40 [95% CI, 0.25-0.73]; P < .001; NNT, 18 [95% CI, 12-34]). This association was limited to patients undergoing nonvascular surgery. β-Blocker exposure was also associated with a lower rate of nonfatal Q-wave infarction or cardiac arrest (RR, 0.67 [95% CI, 0.57-0.79]; P < .001; NNT, 339 [95% CI, 240-582]), again limited to patients undergoing nonvascular surgery.
Conclusions and Relevance 
Among propensity-matched patients undergoing noncardiac, nonvascular surgery, perioperative β-blocker exposure was associated with lower rates of 30-day all-cause mortality in patients with 2 or more Revised Cardiac Risk Index factors. Our findings support use of a cumulative number of Revised Cardiac Risk Index predictors in decision making regarding institution and continuation of perioperative β-blockade. A multicenter randomized trial involving patients at a low to intermediate risk by these factors would be of interest to validate these observational findings.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
    2013-11-07 zhyy88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2053702, encodeId=a32c2053e026d, content=<a href='/topic/show?id=8f5a54442a1' target=_blank style='color:#2F92EE;'>#手术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54442, encryptionId=8f5a54442a1, topicName=手术期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Wed Dec 04 10:26:00 CST 2013, time=2013-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995103, encodeId=cc19199510342, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue May 28 03:26:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085690, encodeId=3c3d208569063, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Nov 07 03:26:00 CST 2013, time=2013-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983408, encodeId=8403198340854, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 12 08:26:00 CST 2013, time=2013-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819239, encodeId=0f79181923980, content=<a href='/topic/show?id=aba89940943' target=_blank style='color:#2F92EE;'>#非心脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99409, encryptionId=aba89940943, topicName=非心脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Jul 19 11:26:00 CST 2013, time=2013-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488252, encodeId=0c14148825229, content=<a href='/topic/show?id=f37799413a6' target=_blank style='color:#2F92EE;'>#非心脏手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99413, encryptionId=f37799413a6, topicName=非心脏手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5438409695, createdName=bnurmamat, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548145, encodeId=80aa154814583, content=<a href='/topic/show?id=6ebe1918eb0' target=_blank style='color:#2F92EE;'>#β-受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19187, encryptionId=6ebe1918eb0, topicName=β-受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae5b14012389, createdName=12498e87m43暂无昵称, createdTime=Sat Apr 27 08:26:00 CST 2013, time=2013-04-27, status=1, ipAttribution=)]

相关资讯

心脏手术时限制输血显示了可比性结果

来源:美国科学促进会  据10月13日出版的《美国医学会杂志》(JAMA 2010;304[14]:1559-1567)上的一项研究显示,在接受心脏手术的病人中,那些采纳了更为严格的红细胞输入指导方针的病人与那些接受较多的输血患者相比,其死亡率和病情严重程度相似。本期《美国医学会杂志》上的另外一则研究对接受心脏手术患者的输血的变化程度进行了检查。   心脏手术与很高的输血率有关联。红细胞性输

NEJM:血糖的严密控制不会改善处于心脏手术期间儿童的健康状况

近日,国际著名杂志New England Journal of Medicine上的一篇研究报告指出,对处于心脏手术期间的婴儿和儿童进行严密的血糖控制(tight glycemic control)并不会降低其感染风险以及改善其恢复状况。接受心脏手术的婴儿和儿童,其通常会表现出高血糖的症状,这或许和健康问题,甚至死亡有关。尽管临床试验的结果比较庞杂,对于成年人重症监护的一些研究显示,使用胰岛素控制

冠心病检测的新技术与增高的心脏手术率和花费相关

   一项新的用于冠心病检测的非侵入性技术与继发侵入性心脏手术率和卫生保健花费增高相关。这些是以斯坦福大学医学院研究人员进行的一项关于医疗受益者的观察性研究为根据的。     在这项出版于《美国医学会杂志》11月16日的研究中,接受冠脉CT血管造影术的患者进行继发侵入性心脏手术的可能性比接受负荷试验(一种更常见的诊断方法)的患者大一倍左右。CT血

王东进:心脏手术微创右腋下直小切口更有优势

  随着心脏外科技术的发展,麻醉、体外循环和围手术期监护等各个方面水平的不断提高,与心脏手术相关的死亡率和并发症发生率逐年下降,与此同时患者对心脏手术的预期疗效也明显提高。在保证手术安全和质量的前提下,为达到美观、减少损伤、加快恢复和减少医疗费用的目的,以小切口手术为主的微创心脏外科手术研究越来越受到重视,心脏外科微创化将是当代医学发展的必然趋势。   近十余年来心脏外科医生尝试应用多种方式,力

CJASN:心脏手术后尿蛋白水平高者出现AKI风险高

  美加联合研究显示,心脏手术后尿蛋白水平较高者,在住院期间出现急性肾损伤(AKI)风险增加。论文9月13日在线发表于《美国肾病学会临床杂志》(CJASN)。   研究纳入2007年7月至2009年12月间接受心脏手术患者1198例,术后0~6小时检测其白蛋白尿和尿白蛋白/肌酐比值(ACR),并用试纸检测尿蛋白水平。以发生AKI(住院期间血肌酐加倍或接受急性透析)为主要终点。   结果为,与水

Baidu
map
Baidu
map
Baidu
map